Nucleic acid therapies offer targeted treatment for genetic diseases, but delivery remains a key hurdle. Explore how advances ...

Surface-engineered LNPs, propelled by clinical successes like patisiran and mRNA vaccines, enable targeted nucleic acid delivery via ligands (antibodies, peptides) and conjugation chemistries (click ...

Gene therapy has emerged as a revolutionary approach to treating genetic disorders by directly addressing underlying genetic abnormalities. However ...

This article highlights the current state of macromolecular gene delivery systems, their applications, and the ongoing ...

The selection of SNS812 affirms the international recognition of Oneness Biotech and Microbio (Shanghai) for their technological platform in nucleic acid drug development and their innovative ...

SNS812, an innovative siRNA drug from Oneness and Microbio (Shanghai), selected for ATS 2025 oral presentation, demonstrating world-leading clinical outcomes in COVID-19 treatment ...

This review discusses the hurdles of systemic siRNA delivery and highlights the recent progress made in lipid-based nanoparticles.

Looking ahead, these advancements could contribute to the development of more personalized medicine, with treatments tailored to individual patients. Enhanced drug delivery systems could also reduce ...

Purdue University researcher David Thompson has developed LENN, a system to deliver nucleic acid-based therapies to targeted cancer cells. His and his team’s research into using LENN to deliver ...